Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer
Introduction
Mouse models are powerful research tools to interrogate how many oncogenes cause cancer [1], [2], [3]. Recently, several robust strategies have been developed to generate transgenic mice that conditionally express a particular gene. Several methods have been utilized, including the Tetracycline Regulatory System (Tet System), the Tamoxifen System, the Cre/loxP System, and the Avian Retroviral Receptor (RCAS-TVA) System. The unprecedented ability to switch gene expression on and off in transgenic mice has been used to demonstrate that the inactivation of a single oncogene can be sufficient to revoke cancer [3]. These results suggest that there are circumstances when the targeted inactivation of a single oncogene will be effective in the treatment of cancer. However, it has also been found in these animal models that tumors can escape dependence upon the oncogene that initiated the process of tumorigenesis [4]. Hence, in order to determine when the inactivation of an oncogene will be effective in the treatment of cancer, it is important to understand how oncogene activation sustains tumorigenesis. Here, we will outline how conditional animal model systems can be used to define when and how oncogene inactivation induces sustained tumor regression.
We will focus our review first on describing the various methods that have been employed to generate conditional mouse models of cancer. We will then discuss how these conditional models have been used to define when oncogene inactivation induces tumor regression; to evaluate the duration and degree to which an oncogene must be inactivated to induce tumor regression; to determine the mechanism by which tumors regress upon oncogene inactivation; and to predict when tumors will relapse and the mechanisms by which they escape dependence upon a particular oncogene. Finally, we will discuss how these strategies may be useful in the development of new, targeted treatments for cancer.
The ability to generate mice that exhibit the tight and regulated control of oncogene expression is useful both to illuminate the cellular and molecular mechanisms by which oncogenes cause and sustain tumorigenesis, and more importantly to validate the use of oncogenes as therapeutic targets for the treatment of cancer.
Section snippets
The Tetracycline and Tamoxifen Systems
The Tet System allows both tissue-specific and temporal regulation of gene expression [5], [6], [7]. It incorporates tissue-specific expression of the tetracycline-controlled transactivator (tTA) and a responder transgene that links the tetracycline response element (Tet-O) to the gene of interest (Fig. 1). The Tet System exists in two versions, Tet-Off (Fig. 1a) and Tet-On (Fig. 1b), depending whether the engineered transcription factor (tTA or rtTA) binds the Tet-O sequence in the absence
The Tet and Tamoxifen Systems
To conditionally regulate oncogene expression in a tissue-specific and temporally controlled manner, most investigators have chosen either the Tet System or the Tamoxifen System. Both approaches have been used to ask the fundamental question, how does oncogene activation induce tumorigenesis, and when is oncogene inactivation sufficient to result in tumor regression? Now many reports have confirmed the surprising finding that the inactivation of even a single oncogene in an established and even
Mechanisms of tumor regression
We and others have previously documented the remarkable finding, using the Tet System to conditionally regulate expression of several different oncogenes, cancer is a reversible disease [3], [13], [49]. Even highly genomically complex and/or metastatic tumors are reversible upon oncogene inactivation [26], [34], [37]. One might imagine that the regression of tumors would involve different pathways depending on the oncogene and the cancer type. However, tumor regression that occurs upon oncogene
Therapeutic implications
The results obtained from these powerful conditional animal model systems will be useful in identifying and validating targets for the therapy of cancer. If turning oncogene expression off leads to tumor regression in an animal model, this oncogene may be a good pharmacological target. Then, by identifying the downstream effector genes critical for this oncogene to sustain tumorigenesis, it may be possible to identify genes that are better drug targets. Moreover, these strategies will be useful
Conclusion
Animal models for conditional oncogene expression are now widely used to investigate many different types of cancer that in many cases closely mimic human cancers [4]. These models have facilitated a detailed analysis of the mechanisms by which specific oncogenes initiate and sustain tumorigenesis, to define when oncogene inactivation will induce tumor regression, and to predict and account for how tumors escape dependence upon oncogenes and relapse. Ultimately, through these models, it may be
References (57)
- et al.
Cancer modeling in the modern era: progress and challenges
Cell
(2002) - et al.
The temporal importance of TNFalpha expression in the development of diabetes
Immunity
(2000) - et al.
Inducible gene knockouts in the small intestinal and colonic epithelium
J. Biol. Chem.
(1999) - et al.
Advancing animal models of neoplasia through in vivo bioluminescence imaging
Eur. J. Cancer
(2002) - et al.
Reversible tumorigenesis by MYC in hematopoietic lineages
Mol. Cell
(1999) - et al.
Conditional expression of fibroblast growth factor-7 in the developing and mature lung
J. Biol. Chem.
(2000) - et al.
Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression
Cell
(2002) - et al.
Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis
Cancer Cell
(2002) - et al.
Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion
Mol. Cell
(1999) - et al.
Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations
Blood
(2003)
Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia
Cancer Cell
Engineering de novo reciprocal chromosomal translocations associated with Mll to replicate primary events of human cancer
Cancer Cell
Cyclin e ablation in the mouse
Cell
Flipping the oncogene switch: illumination of tumor maintenance and regression
Trends Genet
Adenovirus mediated prostate specific enzyme prodrug gene therapy using prostate specific antigen promoter enhanced by the Cre-loxP system
J. Urol.
Improvement of carcinoembryonic antigen-specific prodrug gene therapy for experimental colon cancer
Surgery
Conditional mouse models of sporadic cancer
Nat. Rev. Cancer
Opinion. Cancer revoked: oncogenes as therapeutic targets
Nat. Rev. Cancer
How cancers escape their oncogene habit
Cell Cycle
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters
Proc. Natl. Acad. Sci. U.S.A.
Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter
Proc. Natl. Acad. Sci. U.S.A.
Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice
Proc. Natl. Acad. Sci. U.S.A.
Control of memory formation through regulated expression of a CaMKII transgene
Science
Doxycycline control of prion protein transgene expression modulates prion disease in mice
Proc. Natl. Acad. Sci. U.S.A.
Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy
Hum. Mol. Genet.
A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins
Nucleic Acids Res.
c-MYC: more than just a matter of life and death
Nat. Rev. Cancer
Targeted oncogene activation by site-specific recombination in transgenic mice
Proc. Natl. Acad. Sci. U.S.A.
Cited by (50)
The MYC oncogene is a global regulator of the immune response
2018, BloodCitation Excerpt :Conditional transgenic mouse models have been used to study how MYC initiates and maintains tumorigenesis for several tumor types, including hematopoietic tumors. The suppression of MYC expression in conditional mouse models has been shown to result in rapid and sustained loss of a neoplastic phenotype, which has been described as “oncogene addiction.”6-10,28-37 Initially, MYC was presumed to contribute to tumorigenesis through tumor cell–intrinsic mechanisms, independent of the host or the immune system.
The c-myc Promoter: Still MysterY and Challenge
2008, Advances in Cancer ResearchCitation Excerpt :Nevertheless, a dominant‐negative form of c‐Jun blocked the estrogen‐induced expression of c‐myc mRNA (DeNardo et al., 2005). Coactivators recruited by the ER include p300/CBP, P/CAF, BRG‐1, CARM1, PRMT1, a DRIP/TRAP mediator complex, CIA, SRA, SNURF, a TRRAP‐containing HAT complex, PGC‐1, PELP1, and the three members of the SRC family (p160 family) SRC‐1/NCoA‐1, GRIP1/SRC‐2/TIF2/NCoA‐2, and AIB1/SRC‐3/pCIP/ACTR/RAC3/TRAM1/NCoA‐3, which serve as platforms to recruit HATs and protein methyltransferases (Barnes et al., 2004; Belandia and Parker, 2003; Chen et al., 2001a; Glass and Rosenfeld, 2000; Halachmi et al., 1994; Klinge, 2000; Lemon and Freedman, 1999; Lonard and O'Malley, 2005, 2006; McKenna and O'Malley, 2002; McKenna et al., 1999; Pearce and Jordan, 2004; Rosenfeld et al., 2006; Sauve et al., 2001; Shao and Brown, 2004). Corepressors recruited by the ER include NCoR, SMRT, and REA (Jepsen and Rosenfeld, 2002).
NOTCH1 pathway activation is an early hallmark of SCLT leukemogenesis
2007, BloodCitation Excerpt :In particular, we were aiming to define possible abnormal cellular compartments induced by SCL, which potentially might be targets of secondary genetic hits required for the development of overt malignancy. The use of conditional transgenic models allows the analysis of the initiation, progression, and maintenance of malignant diseases.37 Herein, we developed a conditional transgenic model (lck-ERT2-SCL) by creating a fusion protein between SCL and the mutated ligand-binding domain of the human estrogen receptor (ERT2).
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis
2007, BloodCitation Excerpt :MYC is one of the oncogenes most commonly associated with human cancer.24 Experimentally, the inactivation of MYC has been shown to induce sustained tumor regression in transgenic mouse models of many different tumors, suggesting that MYC may be a good target for cancer treatment.25,–28 However, MYC as a transcription factor is not easy to target directly with small molecules.
MYC inhibitors in multiple myeloma
2021, Cancer Drug Resistance